Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Sadaf ..
 -- 4430 2023-11-10 10:25:12 |
2 format
Jason Zhu
 Meta information modification 4430 2023-11-13 07:26:56 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Sadaf, S.; Hazazi, A.; Alkhalil, S.S.; Alsaiari, A.A.; Gharib, A.; Alhuthali, H.M.; Rana, S.; Aloliqi, A.A.; Eisa, A.A.; Hasan, M.R.; et al. Fork-Head Box Genes in Breast Cancer. Encyclopedia. Available online: https://encyclopedia.pub/entry/51414 (accessed on 31 July 2024).
Sadaf S, Hazazi A, Alkhalil SS, Alsaiari AA, Gharib A, Alhuthali HM, et al. Fork-Head Box Genes in Breast Cancer. Encyclopedia. Available at: https://encyclopedia.pub/entry/51414. Accessed July 31, 2024.
Sadaf, Sadaf, Ali Hazazi, Samia S. Alkhalil, Ahad Amer Alsaiari, Amal Gharib, Hayaa Moeed Alhuthali, Shanika Rana, Abdulaziz A Aloliqi, Alaa Abdulaziz Eisa, Mohammad Raghibul Hasan, et al. "Fork-Head Box Genes in Breast Cancer" Encyclopedia, https://encyclopedia.pub/entry/51414 (accessed July 31, 2024).
Sadaf, S., Hazazi, A., Alkhalil, S.S., Alsaiari, A.A., Gharib, A., Alhuthali, H.M., Rana, S., Aloliqi, A.A., Eisa, A.A., Hasan, M.R., & Dev, K. (2023, November 10). Fork-Head Box Genes in Breast Cancer. In Encyclopedia. https://encyclopedia.pub/entry/51414
Sadaf, Sadaf, et al. "Fork-Head Box Genes in Breast Cancer." Encyclopedia. Web. 10 November, 2023.
Fork-Head Box Genes in Breast Cancer
Edit
This entry is adapted from the peer-reviewed paper 10.3390/biomedicines11082159

Breast cancer has been acknowledged as one of the most notorious cancers, responsible for millions of deaths around the globe. Understanding the various factors, genetic mutations, comprehensive pathways, etc., that are involved in the development of breast cancer and how these affect the development of the disease is very important for improving and revitalizing the treatment of this global health issue.

forkhead genes forkhead proteins FOXA FOXM1

1. Forkhead Box A in Cancer

Pioneer factor forkhead box genes FOXA1/A2/A3 are momentous for the development of endoderm and organs originating from the endoderm. As pioneer factors, they facilitate chromatin access for other transcription factors so that they can carry out their tissue-specific tasks [1][2]. Based on their numerous actions, particularly the apropos triggering of cellular invasion in nearby and outlying tissues and metastasis, DNA damage and mutation, and persistent cell cycle signaling, FOXA1 and FOXA2 do play significant functions in carcinogenesis. By being additionally linked to several malignancies, FOXA1 and FOXA2 exhibit tumor-type-specific characteristics that depend on specific transcriptome connections [3]. Lung, prostate, and esophageal cancers are all highly linked with the presence of FOXA1 upregulation [4]. In bladder cancer, the diminished expression of the FOXA gene has been associated with muscle-invasive tumor progression, which then advances to the metastatic phase [5].
The two main cancer malignancies that are affected by hormones are breast and prostate cancer. FOXA demonstrates a crucial role in the synchronization of estrogen-receptor and androgen-receptor functions, so it is not as startling to discover the presence of forkhead-box A gene expression in ER-positive breast cancer and AR-positive prostate tumors. FOXA1 is expressed in a small fraction of ER-negative breast tumors that express AR [6]. In breast cancer cell lines, the FOXA1 gene is fundamentally manifested when cells express ER. Furthermore, cDNA microarray cluster result analysis associates FOXA1 gene transcripts with other genes, such as ER, GATA-3, and X-box binding protein [XBP-1], and this is a characteristic feature of the luminal subtype A of breast cancer [7][8].
The ER-estrogen-FOXA1-GATA-3 axis has a determining function in the beginning and/or progression of luminal-type tumors, and this has recently been proposed by the attestation of FOXA1 as a pioneer factor, essential for the expression of the bulk of estrogen-inducible genes, like a breast tumor [9][10]. As luminal type A breast cancer tumors require estrogen for survival and growth, such patients respond better to estrogen therapy, whereas patients with luminal type B breast cancer tumors have a meager prognosis. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER2) are two examples of growth factor receptors that can mediate redundant survival and proliferation pathways in luminal type B malignancies [11].
Thus, FOXA1 has been commendatory with a luminal subtype and favorable prognosis. As FOXA is a pioneer factor, it becomes easy for estrogen to target the regulatory regions in target genes in healthy breast tissue [12]. Additionally, there appears to be a positive regulatory loop between the FOXA1 and the target genes, and changes in this pathway may result in the cells undergoing a malignant transformation. Prior research demonstrates the significance of FOXA1 expression for a favorable prognosis in steroid-dependent carcinomas, like breast and prostate cancers [13]. In basal-like (or triple-negative) breast cancer cell lines, the in vitro suppression of FOXA2 gene expression decreases proliferation and mammosphere development. FOXA2 is connected to more aggressive tumor behavior because it plays a part in the mechanisms of proliferation [14]. In light of these encouraging findings, FOXA2 is supported as a peculiar remedial target for the nursing of a particular category of people with triple-negative/basal-like breast cancer who are at an increased danger of recurrent cancer [15].

2. Forkhead Box M1 in Cancer

FOXM1 is a predominant modulator of cancer growth and metastasis that is selectively expressed in dividing cells [16]. The higher expression of FOXM1 is linked to lower patient survival, while the overproduction of the FOXM1 gene transcript is prevalent in breast cancer [17]. FOXM1 helps cancer cells evade growth suppressors by turning on cell-cycle regulators and anti-oxidant genes and the advancement along the EMT composition, annexation, and the evolution of pre-metastatic niches [17][18][19]. Fascinatingly, inhibiting FOXM1 alone is thought to be sufficient for addressing multiple cancer processes [20].
FOXM1 is so ubiquitous in breast cancer that all subtypes produce the FOXM1 gene transcript that also happens to be indispensable for treatment resistance, the transition of epithelial cells to mesenchymal cells (EMT), annexation, and metastasis [21]. FOXM1 pronouncement fluctuates with the cell cycle phase under normal physiological circumstances, rising during the S phase, and is the most pronounced in the G2-M phase. In pre-symptomatic types of breast cancer, FOXM1 is necessary for augmentation and mitosis and modulates the genes transcription factors, such as p27kip1, cyclin D1, and cdc25, that are affiliated with cell division modulation at the G1-S and G2-M transition points. As an autonomous feature of estrogen concentrations, the reduced levels of FOXM1 abate the propagation of mammary tumor cells without alleviating cell death [22]. FOXM1 controls breast cancer mitosis and EMT, coupled with proliferation. FOXM1 depletion encourages polyploidy and chromosomal instability. Because of defective cytokinesis that results in centrosomal expansion and the development of multipolar spindles, stable FOXM1 knockdown may cause mitotic catastrophe.
When analyzed against customary breast tissue, the FOXM1 transcript is more abundant in breast cancers [23]. When compared to normal breast tissues (n = 14), fibrocystic breast tissues (n = 17), or fibroadenomas (n = 7), penetrating ductal breast carcinomas (n = 194) show upregulated FOXM1 transcription [24]. Real-time PCR analysis and immunohistochemical staining both demonstrate the higher transcription levels of the FOXM1 gene in mammary tumor tissues, as opposed to normal breast tissues [23][24].
FOXM1 controls ER-alpha production, transitions, and interactions, as well as the transcriptional activity in luminal subtypes; forkhead binding domains have been discovered in the ESR1 (ER alpha) promoter zone [25][26]. It has been substantiated that an inverse relation exists between the FOXM1 transcript and beta1 production magnitude, prompting that ER-beta1 appears to suppress the transcription of the FOXM1 gene by expelling ER-alpha molecules from the FOXM1 gene promoter site in ER-positive breast tumors [27]. In patients with luminal subtypes receiving supportive chemotherapy alone or receiving the drug tamoxifen alone, noticeably increased FOXM1 transcript levels were observed, corresponding with a diminished outlying metastasis-free situation, without relapse, or comprehensive survival rates, suggesting a potential link to noncompliance in terms of chemotherapy or endocrine therapy [28][29].
By enhancing YAP1’s transcriptional activity, FOXM1 increased the capacity of triple-negative breast cancer cells to proliferate, form clones, and migrate. Additionally, FOXM1 preserved cell stemness by using the Hippo pathway. YAP1-TEAD binding inhibitor Verteporfin decreased the levels of OCT4 and NANOG molecules, but they were increased by XMU-MP-1. In conclusion, FOXM1 enhanced the advancement of mammary tumors through the Hippo pathway and can be utilized as a novel approach to treating breast cancer [30].

3. Forkhead Box O in Cancer

Among the FOX proteins, the FOXO subclass is undeniably the one that attracts the most attention from researchers. Different biological processes are carried out by each FOXO protein. For instance, FOXO1 is crucial for angiogenesis, whereas FOXO3A is crucial for the development of ovarian follicles [31]. As opposed to FOXM and FOXC subclasses, which are true oncogenes, FOXO proteins have a variety of catabolic and anabolic processes at several levels. The imbalanced modulation of FOXOs may result in tumor proliferation [32]. Cellular energetics, evading growth suppressors, replicative immortality, initiating angiogenesis, genomic unpredictability and mutation, and assisting proliferative signaling are just a few of the hallmarks of cancer that FOXOs play a part in [33][34][35][36].
The carcinogenic functions of FOXOs in breast cancer are demonstrated by their control of numerous procedures necessary for carcinogenesis. Reassessing the functions of FOXO proteins in tumor proliferation is crucial for this reason. The majority of the post-translational modifications control FOXOs. For instance, the PI3K/Akt/Insulin (phosphorylated by phosphatidylinositol 3-kinase/RAC-serine/threonine-protein kinase) signaling pathway typically modifies FOXO members [34]. It has been demonstrated that by inhibiting Akt, ERK, and IKK via the current treatment methods, the indirect overexpression of FOXOs is enabled [35].
Enough research has led people to conclude that SIRT and FOXO genes have a predominant part in the evolution of tumors, but their functions in metastasis are still ambiguous. SIRT1, p21, p53, E2F1, and FOXO protein expression levels were higher in 67NR groups in primary tumors. SIRT1, E2F1, and FOXO protein expression concentrations were discovered to be elevated in metastatic tissues, but p53 and p21 expression levels were found to be demoted. The molecular role of the SIRT and FOXO proteins in the development and spread of tumors was also empirically supported by IPA analysis. Thus, FOXO proteins and SIRT1 work together to promote metastasis [37].
FOXO3A dephosphorylation, nuclear and cellular translocation, and the disruption of its interaction with SirT6 are brought on by the protracted therapy of luminal breast cancer cells with AKT inhibitors, which also causes FOXO3A acetylation coupled with BRD4 recognition. When BRD4’s BD2 domain is recognized by acetylated FOXO3A, the BRD4/RNAPII complex is attracted to the CDK6 gene promoter and causes the production of transcription factors. The in vitro and in vivo disinclination of luminal breast cancer cells to AKT inhibitors is considerably mitigated by the pharmacological suppression of either BRD4/FOXO3A association or CDK6 [38]. Glucose, amino acids, and lipid metabolism are just a few of the metabolic processes that FOXOs play a role in. Consequently, FOXOs could open a wide therapeutic window for the application of metabolic disruptors [39].

4. Forkhead Box P in Cancer

A functionally varied subfamily of proteins known as the FOXP proteins is notable for its coactive participation in development during the embryonic stage, including brain development [40]. The FOXP subfamily has also been shown to have an integral role in language and speech development centers in the brain, autoimmune diseases, and cancer initiation and progression [41][42][43]. Angiogenesis, cell death resistance, maintaining proliferative signals, tumor-promoting inflammation, evading growth suppressors, and genomic instability and mutation are all factors that contribute to FOXP-dependent cancer proliferation and development. The ability of the FOXP subfamily to form similar and distinctive dimers with paralogs, known as FOXP1/2/4 interactions, is one of its distinctive characteristics [40].
FOXP2 plays a dual function in the development of cancer and oncogenesis, primarily acting as a repressor. For instance, FOXP2 can interact with CTBP1, which is a transcriptional corepressor known for controlling and targeting the production and regulation of various tumor inhibitors, such as BAX, PTEN, and p16 [44]. In epithelial cancerous cell lines, including breast cancer and lung cancer, FOXP1 functions as a tumor suppressor and is typically thought of as a transcriptional repressor. However, B-cell lymphomas overexpress FOXP1, and individuals who have increased FOXP1 expression typically have a substandard prognosis. In particular, FOXP1 is related to the proliferation of B cells throughout lymphocyte development [45]. Breast cancer, prostate cancer, and gastric cancer had better prognoses than NSCLC, colorectal cancer, and cervical cancer when FOXP3 is overexpressed [46].
When compared to wild-type cells, FOXP3-overexpressing MDA-MB-231 cells exhibited an enrichment of a gene signature linked to apoptosis, according to gene set enrichment analysis. Further investigation revealed that FOXP3-MDA-MB-231 cells have elevated levels of programmed cell death 4 (PDCD4), a crucial protein implicated in cell death. Both Western blotting and reverse-transcription-quantitative PCR demonstrated that FOXP3 increased the production of PDCD4 in mammary tumor cells. A public database examination of clinical samples revealed an association between PDCD4 expression levels and the symptomatic stages of breast cancer [47].

5. Forkhead Box C in Cancer

The FOXC subfamily has been shown to play a vital part in cardiovascular development [48]. In fact, it has been proven that embryos without FOXC1/FOXC2 expression manifest several abnormal cardiovascular phenotypes and even die within a few days of delivery [49]. Angiogenesis, invasion, metastasis, invasion of growth eliminators, genomic instability and mutation, and the maintenance of proliferative signals are the primary functions of FOXC1 and FOXC2 in cancer. Breast cancer, liver cancer, Hodgkin’s and non-lymphoma, Hodgkin’s pancreatic cancer, and endometrial cancer are only a few of the cancers that FOXC1 is linked to [50][51].
In a breast cancer model, a reduction in FOXC1 expression retards the development of cancer cells and converts fibroblast-like cells to epithelial cells. Furthermore, patients with basal-like breast cancer have a worse forecast, and FOXC1 is positively linked to cancer spread [52]. When FOXC1 activates the EMT process in hepatocellular carcinoma, the cancer cells are better able to migrate and invade. Patients with increased levels of FOXC1 expression typically have worse prognoses [53].
Like FOXC1, FOXC2 plays a significant part in the evolution of different cancer types. Breast, stomach, lung, cervical, prostate, and ovarian cancers all exhibit the overexpression of FOXC2. Notably, FOXC2 has the capacity to modulate the general upkeep of tumor cells and is involved in lipid alteration via kinases in tumor cells, whereas the role of FOXC1 in cancer metabolism is still a topic of research [54].
Thus, it is evident that the FOXC subfamily has a fundamental function in cancer development and progression, which makes it noteworthy. Further research on related cellular pathways could assist with the production of more efficient therapeutic strategies and better outcomes.

6. FOX Proteins in Cancer Drug Resistance

On a clinical level, a significant hindrance to current cancer therapies is the emergence of opposition to both established and recently developed molecular-targeted medicines [55]. It is interesting to note that FOX gene proteins are also related to several resistance pathways and the operations of both traditional cytotoxic chemotherapy and molecular-targeted medicines. Changes in drug targets, drug metabolism, cancerous stem cell populations, death signals, cell persistence, and drug targets all have functions in the relationships between forkhead-box proteins and the emergence of drug resistance [56]. For instance, resistance to chemotherapy and a worse mortality rate in cancer patients is strongly related to diverse FOXM1 or FOXOs protein production levels.
In breast cancer patients, Nijmegen breakage syndrome gene-targeting by FOXM1 can regulate senescence induced by DNA damage and epirubicin resistance [57]. FOXM1 targets the X-lined prohibitor of the apoptosis gene (XIAP), and survivin can be a potential component for resistance in breast cancer patients [47]. Deregulating FOXM1 transcript production to control kinesin family member 20A in mitotic catastrophe can regulate paclitaxel resistance [58]. In recurrent cancers, FOXC1 production is correlated with reduced or extremely traced estrogen receptor (ER) expression, and through inhibiting GATA binding protein 3 binding, FOXC1 participates in ER silencing and has been linked to endocrine resistance [49]. It has been proposed that platelet-derived growth factor receptors are key players in the chemoresistance of breast cancer caused by FOXQ1, which could have consequences for the evolution and maturation of novel therapeutic regimens for the disease [59]. By regulating p27, FOXD1 can assist the development and chemoresistance of breast cancer [60]. By activating interleukin-6, FOXA1 is downregulated, which results in breast tumor cells that are opposed to tamoxifen, having the characteristics of cancer stem cells [61]. By prohibiting FOXC2-mediated EMT, FOXF2 may further aid the multidrug opposition of basal-like breast cancer [62].
Alternatively, the abnormal stimulation of the repair of DNA damage may be related to genotoxic treatment resistance as well as cancer progression and cancer initiation. Aiming for FOXM1 and FOXOs has the potential to treat genotoxic drug resistance because convincing data demonstrates that the FOXOs-FOXM1 forkhead transcription factor axis alters the response to DNA mutation [63][64]. A significant obstacle to contemporary cancer therapy in the clinic is the emergence of an aversion to both established prosaic medicines and recently developed molecularly targeted therapies. Intriguingly, unregulated signaling through the transcription factors FOXO3 and FOXM1 is consistently connected to the resistance procedures to “traditional” cytotoxic chemotherapies and to molecularly targeted treatment remedies. This is because FOXM1 and FOXO3 are involved in controlling the genes correlated with vital drug-action-related biological mechanisms like drug efflux, stem cell renewal, cell survival, DNA repair, and dysregulated mitosis [65]. Changes in drug metabolism, drug targets, the amount of cancer stem cells, the pace at which DNA damage is repaired, and cell survival and death signals can all have a function in the pathways for the evolution of drug resistance.
FOXM1 has been shown to be vital in mediating resistance to genotoxic substances, such as radiation and epirubicin, through the modulation of genes associated with DNA damage repair, such as BRIP1 and NBS1. Similar to this, it has been shown that FOXM1 overexpression confers the development of cisplatin resistance in breast tumor cells. In contribution, the overproduction of FOXM1 transcript increases docetaxel’s chemoresistance in gastric cancer and may serve as a prognostic predictor [66][67][68]. In order to promote the restoration of or resistance to the DNA damage caused by genotoxic chemicals, FOXM1 overexpression or FOXO3 suppression can stimulate the functions of genes that respond to DNA damage. This helps malignant cells endure the genotoxic effects of anticancer drugs. In order to liaise mitotic cataclysm and senescence in breast cancer cells, paclitaxel can also downregulate FOXM1. The diminished expression of FOXM1 transcript is at least partially responsible for this cytotoxic function. In agreement with this, the overexpression of FOXM1 forkhead box is associated with a reduced mortality rate for breast cancer patients and can augment the tolerance of breast cancer cells to the medicine paclitaxel [69].
As an alternative, using the right drug cocktails to cure cancer and control drug tolerance is a well-established basis in cancer treatment remedies. Recent research has demonstrated that PI3K-Akt pathway inhibitors, like OSU-03012, have been demonstrated to improve FOXO3A dephosphorylation and nuclear translocation in breast tumor cells and can activate FOXO3A [70]. Furthermore, an additional Akt inhibitor, MK-2206, can activate and dephosphorylate FOXO3A and may work in conjunction with doxorubicin and other standard genotoxic medications to treat liver cancer [71]. Understanding the upriver modulators, downriver targets, and cell-level roles of FOX transcripts, as well as the transcriptional programs they orchestrate (in particular, cancer disease states), is crucial for determining the best possible targets for modifying FOX proteins [72].

7. Negative Regulation of FOX Proteins by miRNAs

A novel bracket of short RNAs that do not code for proteins called miRNAs is 18–25 nucleotides in length. MiRNAs are deeply rooted in several biological processes, including cell differentiation, stress resistance, and cancer, according to studies from the last 10 years. Numerous studies have shown that miRNAs in cancer patients under diverse clinical circumstances regulate FOX proteins. Recent research suggests that several malignancies, including esophageal cancer, colorectal cancer, hepatocellular carcinoma, and triple-negative breast cancer, specifically target the FOX genes [73][74][75][76]. For instance, miR-342 has been shown to reduce the levels of FOXM1 and FOXQ1 production by intuitively collaborating with the presumptive 3’-UTR binding sites of these genes, preventing colorectal cancer cells from proliferating, migrating, and invading in a xenograft animal model [73]. One of the direct targets of miR-204 is FOXM1, and miR-204’s functional impact on esophageal cancer cell lines depends on FOXM1 [74]. By altering its immediate objectives, such as FOXQ1, FOXG1, and FOXE1, miR-422a expression was restored, which greatly reduced tumor development and liver metastasis in xenograft tumor models [77].
In HER2 (or erb2)-positive breast cancer, a humanized model of anti-HER2 monoclonal antibody (Ab) called Herceptin has proved to be a successful HER2-targeted remedy for preliminary and metastatic HER2-positive breast cancer [78]. In maintaining the fundamental IGF2/IGF-1R/IRS1 signaling in cells sensitive to Herceptin, FOXO3A modulates certain miRNAs to supervise IGF2 and IRS1 production [79]. The fundamental function keeps PPP3CB, a sub-unit of serine/threonine protein phosphatase 2B, expressed to prevent the phosphorylation of FOXO3A (p-FOXO3A), resulting in the production of miRNAs that target IGF2 and IRS1. Nevertheless, Herceptin-resistant cells have elevated p-FOXO3A concentrations as a result of PPP3CB transcriptional suppression, which breaks the negative feedback inhibitory arc created by FOXO3A and the miRNAs. This causes IGF2 and IRS1 to be upregulated [80]. The importance of a negative feedback inhibitory arc for IGF-induced signaling in cellular functions and maintenance has been demonstrated [81]. Additionally, a considerably higher level of IGF2 in the blood and IRS1 was found in the tumors of patients with breast cancer who did not respond well to Herceptin-containing regimens.
The production of FOXM1 is upraised in breast cancer cells, and patients with breast cancer have a substandard prognosis and transient overall endurance as a result. In response to FOXM1 knockdown, Hamurcu Z, et al. used microarray technology to analyze the production outlines of 752 miRNAs in extremely militant and advanced triple-negative breast cancer (TNBC) cells. They found 13 miRNAs that showed differential expression, with 3 miRNAs stimulation and 10 miRNAs downregulated [82]. Increased FOXM1 expression is linked to diminished chances of patient mortality and induces the production of the tumor inhibitor miR200b-5p and oncomiR miR-186-5p, showing that the FOXM1/miRNA signaling pathway may be associated in the improbable prognosis of cancer patients and symbolizes a prospective medicinal target in triple-negative breast cancer [83].
It has been documented that miRNA-937 (miR-937) has aberrant expression in stomach and lung malignancies, where it may play tumor-inhibitor or carcinogenic functions in tumor proliferation, inclusive of the development of cancer [84][85]. MiR-937 expression levels were noticeably lower in breast cancer, and the TNM stage and lymph node metastases were substantially linked with this underexpression. The upregulation of miR-937 was suppressive of breast cancer cells’ capacity to proliferate, develop, migrate, and invade. Additionally, ectopic miR-937 expression slowed the expansion of breast cancer tumors in patients. In breast cancer, it was discovered that miR-937 directly targets the forkhead box Q1 (FOXQ1) mRNA, and FOXQ1 was shown to be overexpressed, and this overexpression exhibited a negative correlation with miR-937 expression.

8. FOX Family and Stem Cells

The consumption of embryonic stem (ES) cells in fundamental science, regenerative medicine, and drug development is a possibility. Recent research revealed a link between the FOX family and stem cells. In luminal breast cancer, there is a link between the number of carcinogenic stem cells (CSCs) and FOXA1 expression (BC). The production of FOXA1 transcript and the genes associated with stemness have been discovered to be more elevated in mammosphere-forming cells than in adherent culture cells [86]. A study found that when embryonic stem cells differentiate, FOXA2 modulates nucleosome depletion and gene activation. Additionally, it was demonstrated that FOXA3 contributed to the demarcation of ESCs into endoderm [87].
Furthermore, FOXC1 is found to be highly expressed in basal-like breast cancer (BLBC). It promotes the migration and invasion of cancerous cells by activating the NF-KB signaling pathway. Hedgehog signaling has also been found to be activated in cancerous cells that have an increased production of FOXC1 transcript. The FOXC1 gene has also been demonstrated to be in negative correlation with the expression of estrogen receptors in cancerous cell membranes [75].
Maintaining blood-producing stem and progenitor cells in the myeloid tissue necessitates the maintenance of niches. By increasing CXCL12 and stem cell factor production and promoting the generation of CXC chemokine ligand (CXCL)12-abundant reticular (CAR) cells, FOXC1 is a crucial governor of this niche establishment [88]. Additionally, it was discovered that FOXC1 controls stem cell quiescence and conserves the chronic tissue-regenerating potential of stem cells by sustaining the hair follicle stem cell niche [89]. FOXC1 controls early cardiomyogenesis, as well as the utilitarian characteristics of cardiomyocytes derived from ESCs [90]. FOXC2 overexpression was ample in bringing about CSC characteristics and unprompted metastasis in mutated human breast epithelial cells, similar to FOXC1 expression [91]. Likewise, a gene induced by forkhead-box C2 has a production trademark that was enhanced in the EMT and CSC-containing claudin-low/basal B breast cancer subtype [92].
FOXD3 is crucial in the control of EpiSCs. Downriver of the Wnt/-catenin signaling suppressor, self-renewal is mediated by overexpression of FOXD3 [93]. As a reprogramming mediator, FOXF1 aids in the reprogramming toward stemness, whereas FOXF2 decreases the frequency of Lgr5+ stem cells by blocking Wnt signaling in intestinal fibroblasts [94][95]. Inhibition of Wnt/-catenin signaling promotes the growth of Epiblast stem cells. Blocking of all Wnt proteins can lead to excessive catenin retention in the cytoplasm. FOXD3 has been shown to be a key inhibitor of IWR-1 (a Wnt inhibitor), leading to the formation of a catenin destruction complex.
Epithelial-mesenchymal metamorphosis and cancerous stem cells in pancreatic cancer are caused by FOXM1 overexpression [96]. The pulmonary vasculature’s embryonic development depends on FOXM1, which is also involved in colon CSC proliferation and self-renewal. By controlling the primary stem cell regulator SOX2, FOXM1 encourages the stemness of glioblastoma [97].

9. Members of the FOX Family as Drug Targets for Cancer Therapies

FOX proteins are climacteric controllers of various cellular and biological procedures. They have been proven to be crucial members of various pathways contributing to unhindered proliferation and tumorigenesis. Therefore, it is only just that drug therapies to block and/or alter such pathways be developed to treat different cancers.
In many cancers, the FOXM1 gene is exacerbated. Reactive oxygen species and oncogenic signaling pathways encourage its expression. It enhances cell migration, causes the epithelial-mesenchymal transition (EMT) composition in tumors, and creates a premetastatic niche in the distant metastasized organs. In addition, FOXM1 promptly initializes genes that are implicated in numerous stages of metastasis. FOXM1 is a vital player in the modulation of tumor magnification and metastasis. Thiostrepton slows the progression of laryngeal epidermoid carcinoma and breast cancer while inducing apoptosis [98].
Siomycin A was discovered to be a FOXM1 inhibitor that suppressed FOXM1’s downriver gene targets, including Cdc25B, survivin, and CENPB. In pliable agar, siomycin A had the capacity to slow down the development of cells independent of anchoring. Furthermore, siomycin A selectively induced apoptosis in metamorphosized cells but not in unmetamorphosed cells of similar origin [99]. Treatment with a cell-permeable ARF26-44 peptide (FOXM1 inhibitor) decreased angiogenesis and tumor cell development and caused a consequential escalation in cell death within the HCC region but not in the surrounding healthy liver tissue. Several different human hepatoma cell lines were treated with the ARF peptide, and this caused the cells to die [100].
The FOXO family portrays a function in the progression of diabetes, cancer, and other human disorders. Several FOXO1 direct-targeting therapeutic candidates are known to be under development, and some of them have already received patent protection. The intracellular location and functionality of FOXO proteins have been demonstrated to be affected by the small-molecule drugs D4476 and ETP-45658 [101]. Numerous malignancies have a negative correlation with FOXO3A. Adenovirus infection can effectively suppress the development of melanoma cells and cause a rapid loss of cell viability by overexpressing FOXO3A/triple mutant (TM). Adenovirus infection caused the cell cycle to be arrested and led to the overproduction of FOXO3A/TM in the carcinoma cell lines, according to cell cycle assessments [44].
When compared to healthy mammary tissues, the production of the FOXQ1 protein was considerably increased in cases of basal-like breast cancer. It was also shown that the expression of the genes FOXQ1 and Dachshund homolog 1 (DACH1) was inversely correlated in metastatic and non-metastatic breast cancers and other tumors. Additionally, FOXQ1 helps cancer stem cells regenerate themselves. Diallyl Trisulfide’s targeting of FOXQ1 prevents breast cancer stem cells from proliferating [102].

References

  1. Zhang, G.; Zhao, Y.; Liu, Y.; Kao, L.-P.; Wang, X.; Skerry, B.; Li, Z. FOXA1 defines cancer cell specificity. Sci. Adv. 2016, 2, e1501473.
  2. Lin, L.; Miller, C.T.; Contreras, J.I.; Prescott, M.S.; Dagenais, S.L.; Wu, R.; Yee, J.; Orringer, M.B.; Misek, D.E.; Hanash, S.M.; et al. The hepatocyte nuclear factor 3 alpha gene, HNF3alpha , on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res. 2002, 62, 5273.
  3. DeGraff, D.J.; Clark, P.E.; Cates, J.M.; Yamashita, H.; Robinson, V.L.; Yu, X.; Smolkin, M.E.; Chang, S.S.; Cookson, M.S.; Herrick, M.K.; et al. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS ONE 2012, 7, e36669.
  4. Mirosevich, J.; Gao, N.; Gupta, A.; Shappell, S.B.; Jove, R.; Matusik, R.J. Expression and role of Foxa proteins in prostate cancer. Prostate 2006, 66, 1013–1028.
  5. Lacroix, M.; Leclercq, G. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene in breast cancer. Mol. Cell. Endocrinol. 2004, 219, 1–7.
  6. Oh, D.S.; Troester, M.A.; Usary, J.; Hu, Z.; He, X.; Fan, C.; Wu, J.; Carey, L.A.; Perou, C.M. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J. Clin. Oncol. 2006, 24, 1656–1664.
  7. Carroll, J.S.; Brown, M. Estrogen receptor target gene: An evolving concept. Mol. Endocrinol. 2006, 20, 1707–1714.
  8. Xia, W.; Bacus, S.; Hegde, P.; Husain, I.; Strum, J.; Liu, L.; Paulazzo, G.; Lyass, L.; Trusk, P.; Hill, J.; et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl. Acad. Sci. USA 2006, 103, 7795–7800.
  9. Raychaudhuri, P.; Park, H.J. FOXM1: A master regulator of tumor metastasis. Cancer Res. 2011, 71, 4329.
  10. Li, L.; Wu, D.; Yu, Q.; Li, L.; Wu, P. Prognostic value of FOXM1 in solid tumors: A systematic review and meta-analysis. Oncotarget 2017, 8, 32298–32308.
  11. Park, H.J.; Carr, J.R.; Wang, Z.; Nogueira, V.; Hay, N.; Tyner, A.L.; Lau, L.F.; Costa, R.H.; Raychaudhuri, P. FOXM1, a critical regulator of oxidative stress during oncogenesis. EMBO J. 2009, 28, 2908.
  12. Park, H.J.; Gusarova, G.; Wang, Z.; Carr, J.R.; Li, J.; Kim, K.H.; Qiu, J.; Park, Y.D.; Williamson, P.R.; Hay, N.; et al. Deregulation of FOXM1B leads to tumour metastasis. EMBO Mol. Med. 2011, 3, 21.
  13. Wang, I.C.; Chen, Y.-J.; Hughes, D.; Petrovic, V.; Major, M.L.; Park, H.J.; Tan, Y.; Ackerson, T.; Costa, R.H. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF ubiquitin ligase. Mol. Cell Biol. 2005, 25, 10875.
  14. Radhakrishnan, S.K.; Gartel, A.L. FOXM1: The Achilles’ heel of cancer? Nat. Rev. Cancer 2008, 8, 242.
  15. O’Regan, R.M.; Nahta, R. Targeting Forkhead Box M1 Transcription Factor in Breast Cancer. Biochem. Pharmacol. 2018, 154, 407–413.
  16. Wonsey, D.R.; Follettie, M.T. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 2005, 65, 5181–5189.
  17. Bektas, N.; Haaf, A.T.; Veeck, J.; Wild, P.J.; Lüscher-Firzlaff, J.; Hartmann, A.; Knüchel, R.; Dahl, E. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 2008, 8, 42.
  18. Madureira, P.A.; Varshochi, R.; Constantinidou, D.; Francis, R.E.; Coombes, R.C.; Yao, K.-M.; Lam, E.W.-F. The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J. Biol. Chem. 2006, 281, 25167–25176.
  19. Sanders, D.A.; Ross-Innes, C.S.; Beraldi, D.; Carroll, J.S.; Balasubramanian, S. Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells. Genome Biol. 2013, 14, R6.
  20. Horimoto, Y.; Hartman, J.; Millour, J.; Pollock, S.; Olmos, Y.; Ho, K.K.; Coombes, R.C.; Poutanen, M.; Mäkelä, S.I.; El-Bahrawy, M.; et al. ERbeta1 represses FOXM1 expression through targeting ERalpha to control cell proliferation in breast cancer. Am. J. Pathol. 2011, 179, 1148–1156.
  21. Lu, X.F.; Zeng; Liang, W.Q.; Chen, C.F.; Sun, S.M.; Lin, H.Y. FoxM1 is a promising candidate target in the treatment of breast cancer. Oncotarget 2018, 9, 842–852.
  22. Lee, J.J.; Lee, H.J.; Son, B.H.; Kim, S.B.; Ahn, J.-H.; Ahn, S.D.; Cho, E.Y.; Gong, G. Expression of FOXM1 and related proteins in breast cancer molecular subtypes. Int. J. Exp. Pathol. 2016, 97, 170–177.
  23. Coomans de Brachène, A.; Demoulin, J.B. FOXO transcription factors in cancer development and therapy. Cell Mol. Life Sci. 2016, 73, 1159–1172.
  24. Huang, H.; Tindall, D.J. Dynamic FOXO transcription factors. J. Cell Sci. 2007, 120, 2479.
  25. Zhang, Y.; Gan, B.; Liu, D.; Paik, J.H. FOXO family members in cancer. Cancer Biol. Ther. 2011, 12, 253–259.
  26. Greer, E.L.; Brunet, A. FOXO transcription factors in ageing and cancer. Acta Physiol. 2007, 192, 19–28.
  27. Kloet, D.E.A.; Burgering, B.M.T. The PKB/FOXO switch in aging and cancer. Biochim. Biophys. Acta Mol. Cell Res. 2011, 1813, 1926–1937.
  28. Maiese, K.; Chong, Z.Z.; Shang, Y.C.; Hou, J. Clever cancer strategies with FOXO transcription factors. Cell Cycle 2008, 7, 3829–3839.
  29. Yadav, R.K.; Chauhan, A.S.; Zhuang, L.; Gan, B. FOXO transcription factors in cancer metabolism. Semin. Cancer Biol. 2018, 50, 65–76.
  30. Sin, C.; Li, H.; Crawford, D.A. Transcriptional regulation by FOXP1, FOXP2, and FOXP4 dimerization. J. Mol. Neurosci. 2015, 55, 437–448.
  31. Meerschaut, I.; Rochefort, D.; Revençu, N.; Pètre, J.; Corsello, C.; Rouleau, G.A.; Hamdan, F.F.; Michaud, J.L.; Morton, J.; Radley, J.; et al. FOXP1-related intellectual disability syndrome: A recognisable entity. J. Med. Genet. 2017, 54, 613.
  32. Tao, J.-H.; Cheng, M.; Tang, J.-P.; Liu, Q.; Pan, F.; Li, X.-P. FOXP3, regulatory T cell, and autoimmune diseases. Inflammation 2017, 40, 328–339.
  33. Martin, F.; Ladoire, S.; Mignot, G.; Apetoh, L.; Ghiringhelli, F. Human FOXP3 and cancer. Oncogene 2010, 29, 4121.
  34. Zhang, W.; Duan, N.; Song, T.; Li, Z.; Zhang, C.; Chen, X. The emerging roles of forkhead box proteins in osteosarcoma. J. Cancer 2017, 8, 1619–1628.
  35. Koon, H.B.; Ippolito, G.C.; Banham, A.H.; Tucker, P.W. FOXP1: A potential therapeutic target in cancer. Expert Opin. Ther. Targets 2007, 11, 955–965.
  36. Szylberg, L.; Karbownik, D.; Marszalek, A. The role of FOXP3 in human cancers. Anticancer. Res. 2016, 36, 3789–3794.
  37. Kume, T. The cooperative roles of FOXC1 and FOXC2 in cardiovascular development. Adv. Exp. Med. Biol. 2009, 665, 63–77.
  38. Papanicolaou, K.N.; Izumiya, Y.; Walsh, K. Forkhead transcription factors and cardiovascular biology. Circ. Res. 2008, 102, 16–31.
  39. Elian, F.A.; Yan, E.; Walter, M.A. FOXC1, the new player in the cancer sandbox. Oncotarget 2018, 9, 8165–8178.
  40. Han, B.; Bhowmick, N.; Qu, Y.; Chung, S.; Giuliano, A.E.; Cui, X. FOXC1: An emerging marker and therapeutic target for cancer. Oncogene 2017, 36, 3957.
  41. Ray, P.S.; Wang, J.; Qu, Y.; Sim, M.-S.; Shamonki, J.; Bagaria, S.P.; Ye, X.; Liu, B.; Elashoff, D.; Hoon, D.S.; et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 2010, 70, 3870.
  42. Xia, L.; Huang, W.; Tian, D.; Zhu, H.; Qi, X.; Chen, Z.; Zhang, Y.; Hu, H.; Fan, D.; Nie, Y.; et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology 2012, 57, 610–624.
  43. Wang, T.; Zheng, L.; Wang, Q.; Hu, Y.W. Emerging roles and mechanisms of FOXC2 in cancer. Clin. Chim. Acta 2018, 479, 84–93.
  44. Yao, S.; Fan, L.Y.; Lam, E.W. The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance. Semin. Cancer Biol. 2018, 50, 77–89.
  45. Bach, D.-H.; Lee, S.K. Long noncoding RNAs in cancer cells. Cancer Lett. 2018, 419, 152–166.
  46. Duc-Hiep, B.; Lee, S.K. The potential impacts of tylophora alkaloids and their derivatives in modulating inflammation, viral infections, and cancer. Curr. Med. Chem. 2018, 26, 4709–4725.
  47. Khongkow, P.; Karunarathna, U.; Khongkow, M.; Gong, C.; Gomes, A.R.; Yague, E.; Monteiro, L.J.; Kongsema, M.; Zona, S.; Man, E.P.; et al. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene 2014, 33, 4144–4155.
  48. Nestal de Moraes, G.; Delbue, D.; Silva, K.L.; Robaina, M.C.; Khongkow, P.; Gomes, A.R.; Zona, S.; Crocamo, S.; Mencalha, A.L.; Magalhaes, L.M.; et al. FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance. Cell. Signal. 2015, 27, 2496–2505.
  49. Khongkow, P.; Gomes, A.R.; Gong, C.; Man, E.P.; Tsang, J.W.; Zhao, F.; Monteiro, L.J.; Coombes, R.C.; Medema, R.H.; Khoo, U.S.; et al. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene 2016, 35, 990–1002.
  50. Yu-Rice, Y.; Jin, Y.; Han, B.; Qu, Y.; Johnson, J.; Watanabe, T.; Cheng, L.; Deng, N.; Tanaka, H.; Gao, B.; et al. FOXC1 is involved in ERalpha silencing by counteracting GATA3 binding and is implicated in endocrine resistance. Oncogene 2016, 35, 5400–5411.
  51. Meng, F.; Speyer, C.L.; Zhang, B.; Zhao, Y.; Chen, W.; Gorski, D.H.; Miller, F.R.; Wu, G. PDGFRalpha and beta play critical roles in mediating FOXQ1-driven breast cancer stemness and chemoresistance. Cancer Res. 2015, 75, 584–593.
  52. Zhao, Y.F.; Zhao, J.Y.; Yue, H.; Hu, K.S.; Shen, H.; Guo, Z.G.; Su, X.J. FOXD1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27. Biochem. Biophys. Res. Commun. 2015, 456, 232–237.
  53. Yamaguchi, N.; Nakayama, Y.; Yamaguchi, N. Down-regulation of Forkhead box protein A1 leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6. J. Biol. Chem. 2017, 292, 8136–8148.
  54. Cai, J.; Tian, A.X.; Wang, Q.S.; Kong, P.Z.; Du, X.; Li, X.Q.; Feng, Y.M. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett. 2015, 367, 129–137.
  55. Xie, T.; Geng, J.; Wang, Y.; Wang, L.; Huang, M.; Chen, J.; Zhang, K.; Xue, L.; Liu, X.; Mao, X.; et al. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. Oncotarget 2017, 8, 8574–8589.
  56. Hou, Y.; Zhu, Q.; Li, Z.; Peng, Y.; Yu, X.; Yuan, B.; Liu, Y.; Liu, Y.; Yin, L.; Peng, Y.; et al. The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. Cell Death Dis. 2017, 8, e2659.
  57. Monteiro, L.J.; Khongkow, P.; Kongsema, M.; Morris, J.R.; Man, C.; Weekes, D.; Koo, C.Y.; Gomes, A.R.; Pinto, P.H.; Varghese, V.; et al. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene 2013, 32, 4634–4645.
  58. Kwok, J.M.; Peck, B.; Monteiro, L.J.; Schwenen, H.D.; Millour, J.; Coombes, R.C.; Myatt, S.S.; Lam, E.W. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol. Cancer Res. 2010, 8, 24–34.
  59. Weng, S.C.; Kashida, Y.; Kulp, S.K.; Wang, D.; Brueggemeier, R.W.; Shapiro, C.L.; Chen, C.S. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol. Cancer Ther. 2008, 7, 800–808.
  60. Nestal de Moraes, G.; Bella, L.; Zona, S.; Burton, M.J.; Lam, E.W. Insights into a critical role of the FOXO3a-FOXM1 axis in DNA damage response and genotoxic drug resistance. Curr. Drug Targets 2016, 17, 164–177.
  61. Bullock, M. FOXO factors and breast cancer: Outfoxing endocrine resistance. Endocr. Relat. Cancer 2016, 23, R113–R130.
  62. Weng, W.; Okugawa, Y.; Toden, S.; Toiyama, Y.; Kusunoki, M.; Goel, A. FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor-suppressive miR-342 in human colorectal cancer. Clin. Cancer Res. 2016, 22, 4947–4957.
  63. Sun, Y.; Yu, X.; Bai, Q. miR-204 inhibits invasion and epithelial-mesenchymal transition by targeting FOXM1 in esophageal cancer. Int. J. Clin. Exp. Pathol. 2015, 8, 12775–12783.
  64. Song, G.Q.; Zhao, Y. MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells’ growth and migration. Tumour Biol. 2015, 36, 5001–5009.
  65. Yang, X.W.; Shen, G.Z.; Cao, L.Q.; Jiang, X.F.; Peng, H.P.; Shen, G.; Chen, D.; Xue, P. MicroRNA-1269 promotes proliferation in human hepatocellular carcinoma via downregulation of FOXO1. BMC Cancer 2014, 14, 909.
  66. Luo, L.; Zhang, Z.; Qiu, N.; Ling, L.; Jia, X.; Song, Y.; Li, H.; Li, J.; Lyu, H.; Liu, H.; et al. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. Nat. Commun. 2021, 12, 2699.
  67. Huang, X.; Gao, L.; Wang, S.; McManaman, J.L.; Thor, A.D.; Yang, X.; Esteva, F.J.; Liu, B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010, 70, 1204–1214.
  68. Guertin, D.A.; Stevens, D.M.; Thoreen, C.C.; Burds, A.A.; Kalaany, N.Y.; Moffat, J.; Brown, M.; Fitzgerald, K.J.; Sabatini, D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signalling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell 2006, 11, 859–871.
  69. Ding, M.; Bruick, R.K.; Yu, Y. Secreted IGFBP5 mediates mTORC1-dependent feedback inhibition of IGF-1 signalling. Nat. Cell Biol. 2016, 18, 319–327.
  70. Hamurcu, Z.; Sener, E.F.; Taheri, S.; Nalbantoglu, U.; Kokcu, N.D.; Tahtasakal, R.; Cınar, V.; Guler, A.; Ozkul, Y.; Dönmez-Altuntas, H.; et al. MicroRNA profiling identifies Forkhead box transcription factor M1 regulated miR-186 and miR-200b alterations in triple negative breast cancer. Cell. Signal. 2021, 83, 109979.
  71. Hamurcu, Z.; Ashour, A.; Kahraman, N.; Ozpolat, B. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Oncotarget 2016, 7, 16619–16635.
  72. Yu, L.; Chen, J.; Liu, Y.; Zhang, Z.; Duan, S. MicroRNA-937 inhibits cell proliferation and metastasis in gastric cancer cells by downregulating FOXL2. Cancer Biomark. 2017, 21, 105–116.
  73. Zhang, L.; Zeng, D.; Chen, Y.; Li, N.; Lv, Y.; Li, Y.; Xu, X.; Xu, G. miR-937 contributes to the lung cancer cell proliferation by targeting INPP4B. Life Sci. 2016, 155, 110–115.
  74. Han, X.; Guo, X.; Zhang, W.; Cong, Q. MicroRNA-937 inhibits the malignant phenotypes of breast cancer by directly targeting and downregulating forkhead box Q1. Oncol. Targets Ther. 2019, 12, 4813–4824, Retraction in Oncol. Targets Ther. 2021, 14, 4991–4992.
  75. Wang, J.; Li, W.; Zhao, Y.; Kang, D.; Fu, W.; Zheng, X.; Pang, X.; Du, G. Members of FOX family could be drug targets of cancers. Pharmacol. Ther. 2018, 181, 183–196.
  76. Li, Z.; Gadue, P.; Chen, K.; Jiao, Y.; Tuteja, G.; Schug, J.; Li, W.; Kaestner, K.H. Foxa2 and H2A.Z mediate nucleosome depletion during embryonic stem cell differentiation. Cell 2012, 151, 1608–1616.
  77. Omatsu, Y.; Seike, M.; Sugiyama, T.; Kume, T.; Nagasawa, T. Foxc1 is a critical regulator of haematopoietic stem/progenitor cell niche formation. Nature 2014, 508, 536–540.
  78. Lay, K.; Kume, T.; Fuchs, E. FOXC1 maintains the hair follicle stem cell niche and governs stem cell quiescence to preserve long-term tissue-regenerating potential. Proc. Natl. Acad. Sci. USA 2016, 113, E1506–E1515.
  79. Lambers, E.; Arnone, B.; Fatima, A.; Qin, G.; Wasserstrom, J.A.; Kume, T. Foxc1 Regulates Early Cardiomyogenesis and Functional Properties of Embryonic Stem Cell Derived Cardiomyocytes. Stem Cells 2016, 34, 1487–1500.
  80. Paranjape, A.N.; Soundararajan, R.; Werden, S.J.; Joseph, R.; Taube, J.H.; Liu, H.; Rodriguez-Canales, J.; Sphyris, N.; Wistuba, I.; Miura, N.; et al. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene 2016, 35, 5963–5976.
  81. Hollier, B.G.; Tinnirello, A.A.; Werden, S.J.; Evans, K.W.; Taube, J.H.; Sarkar, T.R.; Sphyris, N.; Shariati, M.; Kumar, S.V.; Battula, V.L.; et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res. 2013, 73, 1981–1992.
  82. Liu, K.; Sun, Y.; Liu, D.; Ye, S. Inhibition of Wnt/beta-catenin signaling by IWR1 induces expression of Foxd3 to promote mouse epiblast stem cell self-renewal. Biochem. Biophys. Res. Commun. 2017, 490, 616–622.
  83. Wei, H.J.; Nickoloff, J.A.; Chen, W.H.; Liu, H.Y.; Lo, W.C.; Chang, Y.T.; Yang, P.C.; Wu, C.W.; Williams, D.F.; Gelovani, J.G.; et al. FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells. Oncotarget 2014, 5, 9514–9529.
  84. Nik, A.M.; Reyahi, A.; Ponten, F.; Carlsson, P. Foxf2 in intestinal fibroblasts reduces numbers of Lgr5 stem cells and adenoma formation by inhibiting Wnt signaling. Gastroenterology 2013, 144, 1001–1011.
  85. Bao, B.; Wang, Z.; Ali, S.; Kong, D.; Banerjee, S.; Ahmad, A.; Li, Y.; Azmi, A.S.; Miele, L.; Sarkar, F.H. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J. Cell Biochem. 2011, 112, 2296–2306.
  86. Jiang, L.; Wu, X.; Wang, P.; Wen, T.; Yu, C.; Wei, L.; Chen, H. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2015, 141, 971–981.
  87. Radhakrishnan, S.K.; Bhat, U.G.; Hughes, D.E.; Wang, I.C.; Costa, R.H.; Gartel, A.L. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006, 66, 9731–9735.
  88. Gusarova, G.A.; Wang, I.C.; Major, M.L.; Kalinichenko, V.V.; Ackerson, T.; Petrovic, V.; Costa, R.H. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J. Clin. Investig. 2007, 117, 99–111.
  89. Hill, R.; Kalathur, R.K.R.; Callejas, S.; Colaço, L.; Brandão, R.; Serelde, B.; Cebriá, A.; Blanco-Aparicio, C.; Pastor, J.; Futschik, M.; et al. A novel phosphatidylinositol 3-kinase inhibitor directs a potent FOXO-dependent, p53- independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Res. 2014, 16, 482.
  90. Gomez-Gutierrez, J.G.; Souza, V.; Hao, H.Y.; Montes de Oca-Luna, R.; Dong, Y.B.; Zhou, H.S.; McMasters, K.M. Adenovirus-mediated gene transfer of FKHRL1 triple mutant efficiently induces apoptosis in melanoma cells. Cancer Biol. Ther. 2006, 5, 875–883.
  91. Kim, S.H.; Kaschula, C.H.; Priedigkeit, N.; Lee, A.V.; Singh, S.V. Forkhead Box Q1 Is a Novel Target of Breast Cancer Stem Cell Inhibition by Diallyl Trisulfide. J. Biol. Chem. 2016, 291, 13495–13508.
  92. Liu, H.; Song, Y.; Qiu, H.; Liu, Y.; Luo, K.; Yi, Y.; Jiang, G.; Lu, M.; Zhang, Z.; Yin, J.; et al. Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. Cell Death Differ. 2020, 27, 966–983.
  93. Perou, C.M.; Sørlie, T.; Eisen, M.B.; Van De Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; et al. Molecular portraits of human breast tumours. Nature 2000, 406, 747–752.
  94. Laganiere, J.; Deblois, G.; Lefebvre, C.; Bataille, A.R.; Robert, F.; Giguere, V. From the cover: Location analysis of estrogen receptor alpha target promoters reveals that foxa1 defines a domain of the estrogen response. Proc. Natl. Acad. Sci. USA 2005, 102, 11651–11656.
  95. Zaret, K.S.; Carroll, J.S. Pioneer transcription factors: Establishing competence for gene expression. Genes. Dev. 2011, 25, 2227–2241.
  96. Carroll, J.S.; Liu, X.S.; Brodsky, A.S.; Li, W.; Meyer, C.A.; Szary, A.J.; Eeckhoute, J.; Shao, W.; Hestermann, E.V.; Geistlinger, T.R.; et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122, 33–43.
  97. Augello, M.A.; Hickey, T.E.; Knudsen, K.E. FOXA1: Master of steroid receptor function in cancer. EMBO J. 2011, 30, 3885–3894.
  98. Sun, H.L.; Men, J.R.; Liu, H.Y.; Liu, M.Y.; Zhang, H.S. FOXM1 facilitates breast cancer cell stemness and migration in YAP1-dependent manner. Arch. Biochem. Biophys. 2020, 685, 108349.
  99. Dilmac, S.; Kuscu, N.; Caner, A.; Yildirim, S.; Yoldas, B.; Farooqi, A.A.; Tanriover, G. SIRT1/FOXO Signaling Pathway in Breast Cancer Progression and Metastasis. Int. J. Mol. Sci. 2022, 23, 10227.
  100. Liu, J.; Duan, Z.; Guo, W.; Zeng, L.; Wu, Y.; Chen, Y.; Tai, F.; Wang, Y.; Lin, Y.; Zhang, Q.; et al. Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. Nat. Commun. 2018, 9, 5200.
  101. Fan, D.; Zeng, C.; Wang, S.; Han, J.; Zhu, L.; Zhao, H.; Zhang, Y.; Lu, J.; Xu, Y. Forkhead box P3 promotes breast cancer cell apoptosis by regulating programmed cell death 4 expression. Oncol. Lett. 2020, 20, 292.
  102. Badve, S.; Nakshatri, H. Oestrogen-receptor-positive breast cancer: Towards bridging histopathological and molecular classifications. J. Clin. Pathol. 2009, 62, 6–12.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Sadaf Sadaf
,
Ali Hazazi
,
Samia S. Alkhalil
,
Ahad Amer Alsaiari
,
Amal Gharib
,
Hayaa Moeed Alhuthali
,
Shanika Rana
,
Abdulaziz A Aloliqi
,
Alaa Abdulaziz Eisa
,
Mohammad Raghibul Hasan
,
Kapil Dev
View Times: 124
Revisions: 2 times (View History)
Update Date: 13 Nov 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback